LMR Partners’s Terns Pharmaceuticals TERN Stock Holding History

LMR Partners’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$27M	Buy	+512,400	New	+$21M	0.06%	173

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

LMR Partners's TERN Position: Q1 2026 in Review

LMR Partners opened a new position in Terns Pharmaceuticals (TERN) in Q1 2026: 400,000 shares worth $21.1M. The stake represents 0.05% of the portfolio and ranks #204 among its holdings. This is a return to the name: LMR Partners previously reported a position in TERN as recently as Q4 2024.

LMR Partners first reported a position in TERN in Q1 2023 and has held it in 4 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

LMR Partners held 400,000 shares of Terns Pharmaceuticals worth $21.1M as of Q1 2026.
Terns Pharmaceuticals was a new LMR Partners position in Q1 2026.
Terns Pharmaceuticals made up 0.05% of LMR Partners's portfolio in Q1 2026, its #204 holding.
LMR Partners first reported a position in Terns Pharmaceuticals in Q1 2023 and has held it in 4 quarters since.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.